Primatene OTC Asthma Inhaler Amended NDA Expected Second Quarter
This article was originally published in The Tan Sheet
Executive Summary
Amphastar Pharmaceuticals "recently received constructive comments from the FDA regarding our studies" and is "in the process of completing what we believe to be our final human factors study" before responding to a complete response letter the agency submitted in 2014, says company President Jason Shandell.
You may also be interested in...
Keeping Track: CDER 2016 Novel Approvals Hold At 22 As US FDA Declines Cempra's Solithera
The latest drug development news and highlights from our FDA Performance Tracker.
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Abbott's ‘Bedrock Of Good Health’ Nutritionals Business Faces Mounting Infant Formula Litigation
Nutritional product business had 5.1% Q1 sales growth and is like Abbott’s other segments, “super well-aligned to the global demographics and trends in health care,” says CEO Ford. But as it defends complaints of damages from powder formulas made at facility found with unsafe levels of bacterial contaminants, Abbott’s also targeted in litigation alleging failure to warn about risk of infants born prematurely developing necrotizing enterocolitis if fed cow’s milk-based formula.